Trilantic Secures $945M Exit for SOFIE Biosciences Amid Radiopharma M&A Wave
Trilantic North America realizes a $945 million exit with the sale of SOFIE Biosciences, capitalizing on surging strategic buyer appetite in the radiopharmaceuticals sector.